Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
Simonelli
C
C
Zanussi
S
S
Comar
M
M
Vaccher
E
E
Giacca
M
M
De Paoli
P
P
Tirelli
U
U
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006678:HIV / Q000302:isolation & purification; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D017493:Leukocyte Common Antigens / Q000032:analysis / Q000276:immunology; D008297:Male; D010865:Pilot Projects; D012367:RNA, Viral / Q000097:blood; D014766:Viremia / Q000188:drug therapy* / Q000276:immunology; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D007376:Interleukin-2; D012367:RNA, Viral; D015215:Zidovudine; D017493:Leukocyte Common Antigens; D016049:Didanosine